2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - 260-262
Mechanisms of adaptation to intrinsic metabolic and proteostatic stress during normal hematopoiesis and malignant transformation include induction of chronic endoplasmic reticulum stress, rewiring of tRNA modifications and metabolic precursor transporters, and aberrant activation of metabolic programs downstream of cell surface molecules, creating lineage-specific targetable dependencies in lymphoid malignancies.
Technology and Procedures, Omics Technologies, Gene Editing, Profiling, Biological Processes, Pathogenesis, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, CML, Study Population, Human
PAPER

487 Ammonia detoxification by glutamine export enables B-cell transformation

Ruifeng Sun, BS, Mark E Robinson, PhD2, Song Wu, PhD3, Yanzhi Feng, BS4, Kohei Kume, PhD5, Markus Müschen, MD-PhD6
1 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States, Department of Immunobiology, New Haven, Connecticut, United States
2 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States, Department of Immunobiology, New Haven, Connecticut, United States
3 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States, Department of Immunobiology, New Haven, Connecticut, United States
4 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States, Department of Immunobiology, New Haven, Connecticut, United States
5 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States, Department of Immunobiology, New Haven, Connecticut, United States
6 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States, Department of Immunobiology, New Haven, Connecticut, United States

Background and Significance: During progressive malignant transformation, pre-malignant B-cell clones undergo profound metabolic rewiring to meet the energy demands of increased proliferation and biomass accumulation. Many of these changes involve uptake of glucose and other nutrients via surface receptors. We performed comprehensive surface proteome analyses to identify previously unrecognized dependencies during malignant transformation that could be exploited as future drug targets.

Results: Studying progressive pre-B cell transformation in a leukemic mouse model by cell surface protein capturing and mass spectrometry, we identified a recurrent pattern of surface receptor expression, including 7-fold upregulation of SLC7A5 and its heterodimeric partner SLC3A2. In addition, proteomic results of naïve B-cell activation revealed 166- and 78-fold increase of SLC7A5 and SLC3A2 expression, respectively. SLC7A5 functions as an amino acid antiporter that simultaneously mediates leucine uptake and glutamine export. The ability to uptake leucine is shared by multiple transporters. However, SLC7A5 is the only transporter that mediates glutamine export. Since malignant transformation is known to depend on increased glutamine uptake, we examined the function of SLC7A5 and increased glutamine export during leukemic transformation.

To address the role of SLC7A5 upregulation during malignant B-cell transformation, we developed models of murine and human B-cell malignancies based on inducible Cre-mediated, as well as inducible Cas9-mediated, ablation of SLC7A5. SLC7A5 ablation had moderate effect on cell viability but subverted colony formation capacity and clonal fitness in a competitive growth setting. In addition, genetic deletion and pharmacological inhibition of SLC7A5 resulted in significant reduction of leukemia-initiation capacity in vivo and prolonged survival of transplant recipients. Despite the accumulation of intracellular glutamine upon loss of SLC7A5, mitochondrial respiration and the oxygen consumption rate decreased even though glutamine can provide substrates for the TCA cycle. Notably, glutamine deprivation and pharmacological glutamine scavenging significantly rescued cell fitness, indicating that the dependency of B-cell leukemia on SLC7A5 is tied to glutamine export rather than leucine import.

Glutamine has been studied as an ammonium carrier, where non-hepatic cells incorporate ammonia into glutamine and transport to liver for detoxification via the urea cycle. Here we test the hypothesis that SLC7A5-mediated glutamine export represents a previously unrecognized mechanism for ammonia detoxification that is harnessed by pre-leukemic clones to enable full-blown malignant transformation. Consistent with this idea, we discovered that B-cell leukemia showed increased levels of intracellular ammonia ions upon deletion of SLC7A5.

To determine whether increased intracellular ammonia is responsible for impaired cell fitness, we enforced ammonia flux towards the urea cycle in leukemia cells by overexpressing carbamoyl-phosphate synthetase 1 (CPS1), which is the rate-limiting enzyme of the urea cycle. CPS1 overexpression fully restored competitive fitness of SLC7A5-deficient leukemia cells, suggesting that SLC7A5-mediated glutamine export indeed enables ammonia detoxification and is crucial for leukemia progression. Moreover, we found that SLC7A5-deficient leukemia cells acquired distinct metabolic activity in adaptation to ammonia stress. Metabolomic analysis and isotope tracing of 15N-labelled glutamine based on mass spectrometry revealed that SLC7A5-deficient cells prioritize using glutamine as nitrogen donor for the nucleotide salvage pathway, rather than as carbon donor for the TCA cycle and glutathione synthesis. Consistent with this notion, previous studies have suggested the contribution of nucleotide salvage pathway to ammonia detoxification.

Conclusions: While SLC7A5 is widely recognized as a leucine transporter, our results highlight a previously unrecognized role in glutamine export and ammonia detoxification that is critical for B-cell transformation. Our study elucidated that glutamine export in B-cell leukemia represents a mechanism of ammonia detoxification, and that SLC7A5-deficient leukemia cells activate the nucleotide salvage pathway to adapt to ammonia stress. SLC7A5 and cell adaptation pathways in response to ammonia stress are therefore promising therapeutic targets for treatment of B-cell leukemia.

Ruifeng Sun, BS: No relevant conflicts of interest to declare.